American Lung Association and Pfizer Launch Pneumococcal Pneumonia Vaccination Awareness Campaign
Event summary
- Pneumococcal pneumonia causes approximately 225,000 hospitalizations among U.S. adults annually.
- American Lung Association and Pfizer are launching an educational campaign to encourage vaccination for adults 50+ and those with underlying medical conditions.
- Vaccination recommendations include adults 50+ and those 19–49 with conditions like asthma, COPD, chronic heart disease, and diabetes.
- Adults 65+ are over 10 times more likely to be hospitalized with pneumococcal pneumonia than adults 18–49.
- Campaign aims to increase awareness and access to information and resources for at-risk individuals.
The big picture
The campaign aligns with broader public health efforts to reduce preventable hospitalizations and improve outcomes for at-risk populations. With pneumococcal pneumonia posing a significant burden on the healthcare system, the initiative underscores the importance of targeted vaccination programs. The partnership between the American Lung Association and Pfizer highlights the growing collaboration between non-profits and pharmaceutical companies to address critical health issues.
What we're watching
- Campaign Effectiveness
- How the campaign will impact vaccination rates among at-risk populations.
- Public Health Impact
- Whether increased awareness will reduce hospitalization rates due to pneumococcal pneumonia.
- Partnership Dynamics
- The role of Pfizer's partnership in amplifying the campaign's reach and effectiveness.
Related topics